The actress is participating in the campaign for its third year.
Sumitomo Pharma America
Sumitomo Pharma America (SMPA) is continuing its campaign with actress Holly Robinson Peete which encourages people with overactive bladders (OAB) to be comfortable discussing their conditions.1 The hope is that by making conversations about the condition easier, people suffering from it will feel more empowered to go seek treatment as well.
The Time to Go campaign, which is beginning its third year, is part of the company’s promotion of Gemtesa, a treatment for OAB.
In a press release, Peete, who suffers from OAB, said, “I'm excited to continue this partnership with SMPA to encourage people with OAB to take action. I'm now into my third year of treatment with Gemtesa. Since starting treatment and remaining consistent with my regimen, I have seen a reduction in my OAB symptoms. The impact Gemtesa has had on my OAB symptoms is my motivation to continue treatment and inspire others to do the same, so they too can enjoy activities they love with less running to the bathroom."
Alana Darden Powelll, vice president of marketing for urology at SMPA, added, “Hearing from others who have similar experiences can be comforting for those who may feel like they are alone in their journey with OAB. Holly has been an influential partner and advocate, helping us shed light on the impact of OAB and encouraging patients to seek treatment. This year Holly, along with our Go-Getter ambassadors, continues to break down the stigma associated with the condition and underscore how treatment with Gemtesa may help people alleviate OAB symptoms and help people get back to doing more of what they love with less worrying about their condition."
This is the third year of the campaign, which Robinson has been a part of since its beginning. The campaign was first extended last November.2 In a press release issued at the time, Peete explained, “For years, OAB symptoms kept me from fully enjoying the things I love. Talking to my girlfriends about my symptoms helped me realize I wasn't alone, and that seeking help isn't a sign of weakness, rather it's a step towards taking control.
She continued, “They gave me the confidence to talk to my doctor, who prescribed Gemtesa—and now, a year later, the treatment has helped manage my OAB symptoms so I can enjoy activities with less running to the bathroom. That's why I'm thrilled to continue my partnership with SMPA to educate and empower others to address their OAB."
In the same press release, senior vice president and head of the urology franchise at SMPA Walt Johnson said, “Holly is an influential advocate and voice within the OAB community who is helping break the stigma associated with the condition, and we're excited to continue this important work with her. With the addition of our GEMTESA Go-Getters program, our new ambassadors will join Holly in our mission to create a platform that helps those living with this frustrating condition to feel heard and supported. There is no shame in speaking up about OAB, talking to your doctor, and asking for the help you deserve."
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.